A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Completed · Phase 2 · Has a placebo group

Conditions studied: Hidradenitis Suppurativa

In brief

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

Key facts

Study ID

NCT04493502

Run by

Eli Lilly and Company

People needed

72

Starts

2020-08-26

Expected to finish

2022-10-13

Last updated by the study team

2023-04-28

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a diagnosis of HS for at least 6 months
• Have HS lesions in at least 2 different anatomic areas
• Have inadequate response or intolerance to a 28 day course of oral antibiotics
• Have a total count of abscesses and inflammatory nodules greater than or equal to 4
• Agree to use a topical antiseptic daily
• Agree to stop using topical antibiotics during the study. In certain cases, oral antibiotics will be allowed

You may not qualify if…

• Have more than 20 draining fistulae
• Have received any biologic medication (adalimumab, etc.) for the treatment of HS
• Plan to use oral opioids for HS-related pain during the study
• Uncontrolled depression or suicidal thoughts

Where it is running

• Northwest Arkansas Clinical Trials Center — Rogers, Arkansas, United States
• First OC Dermatology — Fountain Valley, California, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Skin Care Research, Inc — Hollywood, Florida, United States
• Nova Clinical Research, LLC — Miami, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Marietta Dermatology Clinical Research — Marietta, Georgia, United States
• Advanced Medical Research — Sandy Springs, Georgia, United States
• Allcutis Research, Inc. — Beverly, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• ALLCUTIS Research — Portsmouth, New Hampshire, United States
• Duke University Medical Center — Durham, North Carolina, United States
• UC Physicians Office Dermatology — Cincinnati, Ohio, United States
• University Hospitals Case Medical Center — Cleveland, Ohio, United States
• Westmead Hospital — Northmead, New South Wales, Australia
• Sunshine Coast University Hospital — Birtinya, QID, Australia
• The Royal Melbourne Hospital — Parkville, Victoria, Australia
• Fremantle Dermatology — Fremantle, Western Australia, Australia
• Holdsworth House Medical Practice — Sydney, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.